Key result
Therapeutic strategies for diastolic dysfunction remain largely empiric and focus on treating underlying conditions using pharmacologic, nonpharmacologic, and surgical approaches.
This review highlights that while specific therapies for diastolic dysfunction lack large-scale randomized trial evidence, management should focus on treating underlying causes like hypertension and optimizing hemodynamics.
Answers are grounded in this paper and cite their sources.
Management of diastolic dysfunction should target underlying conditions; leaves open the need for RCTs of specific therapies.
Despite the fact that up to 50% of heart failure patients have preserved left ventricular (LV) systolic function, treatment of diastolic heart failure remains largely empiric because there have been no large scale randomized trials evaluating the effects of specific pharmacological agents. Nonpharmacologic, pharmacologic and surgical approaches are available, although its efficacy has not been proven. Treatment should target the underlying pathological condition that causes the diastolic heart failure. For example, coronary artery disease, hypertensive heart disease, hypertrophic obstructive cardiomyopathy, and constrictive pericarditis provide relatively specific therapeutic targets, such as lowering of blood pressure, regression of hypertrophy and fibrosis, and treatment of ischemia, and a complete removal of constricting pericardium. Theoretically, pharmacological agents that facilitate myocardial relaxation and improve LV compliance would be ideal for the treatment of diastolic dysfunction. As a shortterm therapeutic goal, manipulation of the loading conditions (preload, afterload) and control of the heart rate will be crucial. The treatment of underlying condition (e.g. hypertension) should be the ultimate goal for the treatment of LV diastolic dysfunction. Many of the drugs used for the treatment of symptoms of heart failure due to diastolic dysfunction are similar to those of systolic dysfunction, although the rationale for their use, the pathophysiological process that is being altered by the drug, and the dosing regimen may be entirely different. In this review, several therapeutic modalities including pharmacologic, nonpharmacologic, and surgical approaches for primary diastolic heart failure will be discussed.
No takes yet. Share an insight, caveat, or question.
Ha et al. (2009) conducted a review in Diastolic dysfunction. Pharmacologic, nonpharmacologic, and surgical therapies was evaluated. Therapeutic strategies for diastolic dysfunction remain largely empiric and focus on treating underlying conditions using pharmacologic, nonpharmacologic, and surgical approaches.
Synapse has enriched 10 related papers. Consider them for comparative context: